trending Market Intelligence /marketintelligence/en/news-insights/trending/4v1VX3sWXt2XUZkkV0Jf_g2 content esgSubNav
In This List

Astellas, Ironwood constipation drug meets endpoint in phase 3 trial in Japan

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises

Blog

Essential IR Insights Newsletter - Summer July-August 2023

Blog

Insight Weekly: Climate law faces hurdles; US borrowing surges; banks revise uninsured deposits


Astellas, Ironwood constipation drug meets endpoint in phase 3 trial in Japan

Astellas Pharma Inc. and Ironwood Pharmaceuticals Inc. reported that the phase 3 trial of linaclotide for chronic constipation, conducted in Japan, met its primary endpoint.

Linaclotide-treated patients showed statistically significant improvement in mean spontaneous bowel movement frequency compared to placebo-treated patients. The companies will use efficacy and safety data to pursue regulatory approval for the additional indication in Japan.

The drug is approved in Japan as prescription treatment for adults with irritable bowel syndrome with constipation. In the U.S., linaclotide is approved, and sold under the brand name Linzess, for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation.